// App-Quantinova.ai

509 : Safety Profile of Upadacitinib in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase 3 Clinical Program

Researchers

Presenter

  • Ronald van Vollenhoven

Principal Investigators

  • Kevin Winthrop

  • Cristiano A. Zerbini

  • Yoshiya Tanaka

  • Louis Bessette

  • Ying Zhang

  • Nasser Khan

  • Barbara Hendrickson

  • Jose Jeffrey Enejosa

  • Gerd Burmester

Medical Centers

  • Metroplex Clinical Research Center, Dallas, TX,

  • Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands

  • Oregon Health and Science University, Portland, OR

  • Centro Paulista de Investigacoe s Clinicas, Sao Paulo, Brazil

  • University of Occupational and Environmental Health, Kitakyushu, Japan

  • Laval University, Quebec, Quebec, Canada.

  • AbbVie Inc., North Chicago, IL, USA, North Chicago, IL

  • AbbVie, Inc., North Chicago, IL

  • Charite-University Medicine Berlin, Berlin, Germany

Locations

  • United States

  • Netherlands

  • Brazil

  • Japan

  • Canada

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Plasminogen Activator, Urokinase

Drug/Treatment

  • Methotrexate

  • ABT-494

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved